Alnylam Pharmaceuticals (ALNY) Total Liabilities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Total Liabilities data on file, last reported at $4.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 1.08% year-over-year to $4.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.1 billion (down 1.08% YoY), and the FY2025 full-year result was $4.2 billion, changed 0.1% from the prior year.
• Total Liabilities for Q1 2026 stood at $4.1 billion, down from $4.2 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $4.6 billion in Q3 2025 and bottomed at $3.0 billion in Q1 2022.
• The 5-year median for Total Liabilities is $4.0 billion (2024), against an average of $3.9 billion.
• The widest annual swing landed in 2022, when Total Liabilities jumped 32.63%; it then fell 1.08% in 2026.
• A 5-year view of Total Liabilities shows it stood at $3.7 billion in 2022, then advanced by 9.34% to $4.1 billion in 2023, then gained by 3.02% to $4.2 billion in 2024, then gained by 0.1% to $4.2 billion in 2025, then declined by 2.94% to $4.1 billion in 2026.
• The last three Total Liabilities figures came in at $4.1 billion (Q1 2026), $4.2 billion (Q4 2025), and $4.6 billion (Q3 2025), per Business Quant data.

Peer Comparison